Group 1 - The Hong Kong stock market is experiencing a collective rise, with the Hong Kong Stock Connect Innovative Drug ETF (159570) surging over 2% and achieving a trading volume exceeding 1.4 billion yuan [1] - As of 10:25, most constituent stocks of the Hong Kong Stock Connect Innovative Drug ETF (159570) are performing well, with Rongchang Bio rising over 6% and several other companies like CSPC Pharmaceutical, WuXi Biologics, and BeiGene increasing by over 2% [3] - Recent policies have provided support for innovative drugs and medical devices, including discussions on the adjustment of the national medical insurance drug list and optimization of clinical trial approvals [4] Group 2 - The pharmaceutical and biotechnology sector experienced significant declines last week, but the innovative drug sector has shown strong performance year-to-date, indicating a potential for medium to long-term investment opportunities despite short-term adjustments [5] - The China Securities Regulatory Commission has proposed measures to expedite the review and approval process for innovative drug clinical trials, aiming to encourage the development and market entry of innovative drugs [5] - The 2025 mid-term investment strategy emphasizes the importance of both domestic stability and international expansion, highlighting China's competitive advantages in population, manufacturing, and innovation capabilities [6][8] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (159570) has a strong focus on the innovative drug industry, with nearly 72% of its top ten holdings in leading companies [8] - The ETF is characterized by a high concentration in innovative drugs, with an 85% weight in this category, and is currently undervalued compared to historical price-to-sales ratios [8] - The ETF allows for T+0 trading and is positioned as a medium-risk investment suitable for balanced investors [8]
港药回调后连续大涨！港股通创新药ETF(159570)再涨近3%，资金汹涌流入！创新药再获政策支持，把握每一次调整机会！
Xin Lang Cai Jing·2025-06-24 02:55